← Back to all signals
RESEARCH PAPER ANALYSIS

Real-World Experiences Using Atezolizumab + Bevacizumab for the Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Study.

AI interpretation is pending for this paper.

Open original publication →
PMID40507295
JournalCancers
Publication Date2025-05-29
Ingested2026-08-02 12:04 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

Objective: This study aimed to evaluate the characteristics, clinical outcomes, and resource use of patients with unresectable hepatocellular carcinoma (uHCC) treated with first-line (1L) atezolizumab plus bevacizumab (A+B) at five United States (US) institutions: the Mayo Clinic, Houston Methodist, Moffitt Cancer Center, Mays Cancer Center, and University of Arizona. Methods: Treating oncologists extracted data from medical charts of patients with uHCC who were treated with A+B after 1 January 2019. Real-world progression-free survival (rwPFS) and overall survival (OS) were assessed using the Kaplan-Meier method for the overall cohort and for a "trial-like" subgroup with characteristics similar to those in the IMbrave150 trial (Eastern Cooperative Oncology Group Performance Status [ECOG PS] 0-1, Child-Pugh [CP] class A, albumin-bilirubin grade 1-2). Results: Of the 300 patients in the overall cohort (median age of 68 years; 12% ECOG PS ≥ 2; 73% CP A; 26% CP B; median follow-up of 8.7 months), the median rwPFS was 6.8 (95% confidence interval [CI]: 5.8, 8.4) months, and the median OS was 14.4 (95% CI: 12.3, 18.2) months. In the trial-like subgroup (n = 194), the median rwPFS was 8.8 (95% CI: 7.6, 12.1) months and the median OS was 19.5 (95% CI: 14.6, 24.7) months. A significantly lower proportion of patients with CP A compared with CP B (39.7% vs. 73.4%) experienced hospitalization within one year of A+B initiation, whereas hospitalizations due to treatment-related adverse events were similar. Conclusions: This study provides insights into the real-world effectiveness of 1L A+B in a diverse US patient cohort, with results from trial-like patients supporting the reproducible efficacy of A+B in clinical practice.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Mapping intratumoral heterogeneity in adolescent CNS tumors using simultaneous amide proton transfer-weighted signal and 18F-choline PET: A feasibility study. Neuro-oncology advances 57.5 2 Metastatic Neuroblastoma Presenting as Suspected Septic Arthritis: A Case Report. Cureus 52.3 3 Functional Impairment and Its Determinants in Adolescents With Inherited Bleeding Disorders: A Single-Centre Cross-Sectional Study. Cureus 62.0 4 A multimodal precision oncology platform integrating genomics, single-cell transcriptomics, and functional drug screening expands therapeutic options in pediatric brain tumors. bioRxiv : the preprint server for biology 69.2 5 Epigenetic patterns and methylation-based models for robust outcome prediction in osteosarcoma. medRxiv : the preprint server for health sciences 60.8 6 Association of Neuronal Cell Adhesion Molecule (NrCAM) Gene with Autism Spectrum Disorder in Indian Cohorts. Annals of neurosciences 60.0 7 State of Precision Oncology: An Australian Perspective. Journal of immunotherapy and precision oncology 72.9 8 Malignant Giant Cell Tumor of Bone: A Clinicopathological Analysis of 15 Cases. Human mutation 61.1 9 Clinically Suspected Tumefactive Demyelination Mimicking a Brain Tumor in a 10-Year-Old Boy: A Case Report. Clinical case reports 44.6 10 Beyond hemoglobin thresholds: identifying clinical predictors for red blood cell transfusion in pediatric severe anemia. Pediatric research 68.0 11 Distance and interruption: The violence of deportation among families enduring childhood cancer in the United States. Medical anthropology quarterly 56.4 12 Inverted Meckel's diverticulum in adults: two case reports and a systematic review. BMC gastroenterology 73.9 13 Torsion and infarction of a large pediatric mesenteric inflammatory myofibroblastic tumor: a case report. Journal of medical case reports 47.5 14 Preoperative Chemotherapy and Its Efficacy in Pediatric Wilms Tumor: A Systematic Review of Randomized Controlled Trials. Cureus 84.94 15 Fear of disease progression in primary caregivers of children with malignant solid tumors: a latent profile analysis. BMC psychology 66.9 16 Protracted copy number alteration evolution in Barrett's oesophagus leading to oesophageal cancer. medRxiv : the preprint server for health sciences 56.0 17 Editorial: The expanding spectrum of hemophagocytic lymphohistiocytosis: pathogenic mechanisms and therapeutic implications. Frontiers in immunology 33.09 18 DNA methylation profiling reveals novel rhabdomyosarcoma subsets with distinct histologic, genetic and clinical properties. medRxiv : the preprint server for health sciences 57.5 19 Brain microvascular endothelial cell dysfunction during Plasmodium infection does not result from astrocyte-derived wingless-related integration site (Wnt)7a deficiency. bioRxiv : the preprint server for biology 50.9 20 The role of microRNAs in neuroblastoma cell differentiation and their therapeutic potential: a systematic review. Frontiers in oncology 79.54 21 Temporal clinical trajectories and Day+14 landmark stratification of infection risk after CD19 CAR T-cell therapy. Frontiers in cellular and infection microbiology 71.52 22 Co-creating the EndoWatch - a smart wearable device for the management of hypothalamic dysfunction in pediatric brain tumor survivors: a pilot study. Frontiers in endocrinology 69.4 23 Ginsenoside RK3 suppresses osteosarcoma via PRMT5/GPX4-ferroptosis axis and enhances doxorubicin chemosensitivity. Frontiers in pharmacology 59.5 24 Age-dependent differences in SARS-CoV-2 entry-factor expression and innate immune responses between pediatric and adult liver organoids. Frontiers in public health 52.62 25 Health beliefs and parental responses to human papillomavirus vaccination in the Middle East: a theory-informed narrative synthesis guided by the health belief model. Frontiers in public health 81.12 26 Diagnostic potential of Aldo-keto reductase 1B10 in pediatric hepatic malignancies: a narrative, hypothesis-generating translational review based on adult evidence and future research directions. Frontiers in medicine 60.5 27 Mucormycosis beyond the classic host: a case series and narrative literature review from a tertiary Greek hospital. Frontiers in fungal biology 60.5 28 Incidence and mortality of breast cancer among adolescent and young adult women worldwide in 2022 and projections for 2040: Implications for surgery. Breast (Edinburgh, Scotland) 57.5 29 Dynamic Radiologic Severity Index is associated with antifungal treatment but does not independently predict initiation in pediatric acute lymphoblastic leukemia with post-chemotherapy pneumonia. Translational pediatrics 75.18 30 Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE)-like spectrum with a unique NRAS c.182A>G (p.Q61R) variant: a case report. Translational pediatrics 55.2 31 Predictive value of novel inflammatory markers for post-infectious pulmonary embolism in children. Translational pediatrics 61.2 32 Persistent cerebrospinal fluid tumor cells during transient radiographic response in bilateral retinoblastoma with central nervous system involvement: a pediatric case report. Translational pediatrics 57.42
PATIENT-FRIENDLY SUMMARY

Real-World Experiences Using Atezolizumab + Bevacizumab for the Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Study.

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic